The U.S. and Europe have sparked a conflict over COVID-19 vaccine still in development. The tension arose when a multinational pharmaceutical company Sanofi announced its intention to prioritize the distribution of the vaccine to the U.S., in case the company successfully completes the development.

During an interview with Bloomberg, Sanofi’s British CEO Paul Hudson who newly took over the office in last September said, “The U.S. government has the right to the largest pre-order because it’s invested in taking the risk,” so “the Americans will likely get Sanofi’s COVID-19 vaccine before the rest of the world.” Along with its competitor GlaxoSmithKline (GSK), the French-based multinational compa